Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets

Research output: Contribution to journalJournal articlepeer-review

Standard

Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets. / Fonteyne, Margot; Wickström, Henrika; Peeters, Elisabeth; Vercruysse, Jurgen; Ehlers, Henrik; Peters, Björn-Hendrik; Remon, Jean Paul; Vervaet, Chris; Ketolainen, Jarkko; Sandler, Niklas; Rantanen, Jukka; Naelapää, Kaisa; Beer, Thomas De.

In: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Vol. 87, No. 2, 28.02.2014, p. 252-263.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Fonteyne, M, Wickström, H, Peeters, E, Vercruysse, J, Ehlers, H, Peters, B-H, Remon, JP, Vervaet, C, Ketolainen, J, Sandler, N, Rantanen, J, Naelapää, K & Beer, TD 2014, 'Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets', European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, vol. 87, no. 2, pp. 252-263. https://doi.org/10.1016/j.ejpb.2014.02.011

APA

Fonteyne, M., Wickström, H., Peeters, E., Vercruysse, J., Ehlers, H., Peters, B-H., Remon, J. P., Vervaet, C., Ketolainen, J., Sandler, N., Rantanen, J., Naelapää, K., & Beer, T. D. (2014). Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 87(2), 252-263. https://doi.org/10.1016/j.ejpb.2014.02.011

Vancouver

Fonteyne M, Wickström H, Peeters E, Vercruysse J, Ehlers H, Peters B-H et al. Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2014 Feb 28;87(2):252-263. https://doi.org/10.1016/j.ejpb.2014.02.011

Author

Fonteyne, Margot ; Wickström, Henrika ; Peeters, Elisabeth ; Vercruysse, Jurgen ; Ehlers, Henrik ; Peters, Björn-Hendrik ; Remon, Jean Paul ; Vervaet, Chris ; Ketolainen, Jarkko ; Sandler, Niklas ; Rantanen, Jukka ; Naelapää, Kaisa ; Beer, Thomas De. / Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets. In: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2014 ; Vol. 87, No. 2. pp. 252-263.

Bibtex

@article{348a29946b84496d85ced5a3aab39b88,
title = "Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets",
abstract = "Continuous manufacturing gains more and more interest within the pharmaceutical industry. The International Conference of Harmonisation (ICH) states in its Q8 'Pharmaceutical Development' guideline that the manufacturer of pharmaceuticals should have an enhanced knowledge of the product performance over a range of raw material attributes, manufacturing process options and process parameters. This fits further into the Process Analytical Technology (PAT) and Quality by Design (QbD) framework. The present study evaluates the effect of variation in critical raw material properties on the critical quality attributes of granules and tablets, produced by a continuous from-powder-to-tablet wet granulation line. The granulation process parameters were kept constant to examine the differences in the end product quality caused by the variability of the raw materials properties only. Theophylline-Lactose-PVP (30-67.5-2.5%) was used as model formulation. Seven different grades of theophylline were granulated. Afterward, the obtained granules were tableted. Both the characteristics of granules and tablets were determined. The results show that differences in raw material properties both affect their processability and several critical quality attributes of the resulting granules and tablets.",
author = "Margot Fonteyne and Henrika Wickstr{\"o}m and Elisabeth Peeters and Jurgen Vercruysse and Henrik Ehlers and Bj{\"o}rn-Hendrik Peters and Remon, {Jean Paul} and Chris Vervaet and Jarkko Ketolainen and Niklas Sandler and Jukka Rantanen and Kaisa Naelap{\"a}{\"a} and Beer, {Thomas De}",
note = "Copyright {\textcopyright} 2014 Elsevier B.V. All rights reserved.",
year = "2014",
month = feb,
day = "28",
doi = "10.1016/j.ejpb.2014.02.011",
language = "English",
volume = "87",
pages = "252--263",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets

AU - Fonteyne, Margot

AU - Wickström, Henrika

AU - Peeters, Elisabeth

AU - Vercruysse, Jurgen

AU - Ehlers, Henrik

AU - Peters, Björn-Hendrik

AU - Remon, Jean Paul

AU - Vervaet, Chris

AU - Ketolainen, Jarkko

AU - Sandler, Niklas

AU - Rantanen, Jukka

AU - Naelapää, Kaisa

AU - Beer, Thomas De

N1 - Copyright © 2014 Elsevier B.V. All rights reserved.

PY - 2014/2/28

Y1 - 2014/2/28

N2 - Continuous manufacturing gains more and more interest within the pharmaceutical industry. The International Conference of Harmonisation (ICH) states in its Q8 'Pharmaceutical Development' guideline that the manufacturer of pharmaceuticals should have an enhanced knowledge of the product performance over a range of raw material attributes, manufacturing process options and process parameters. This fits further into the Process Analytical Technology (PAT) and Quality by Design (QbD) framework. The present study evaluates the effect of variation in critical raw material properties on the critical quality attributes of granules and tablets, produced by a continuous from-powder-to-tablet wet granulation line. The granulation process parameters were kept constant to examine the differences in the end product quality caused by the variability of the raw materials properties only. Theophylline-Lactose-PVP (30-67.5-2.5%) was used as model formulation. Seven different grades of theophylline were granulated. Afterward, the obtained granules were tableted. Both the characteristics of granules and tablets were determined. The results show that differences in raw material properties both affect their processability and several critical quality attributes of the resulting granules and tablets.

AB - Continuous manufacturing gains more and more interest within the pharmaceutical industry. The International Conference of Harmonisation (ICH) states in its Q8 'Pharmaceutical Development' guideline that the manufacturer of pharmaceuticals should have an enhanced knowledge of the product performance over a range of raw material attributes, manufacturing process options and process parameters. This fits further into the Process Analytical Technology (PAT) and Quality by Design (QbD) framework. The present study evaluates the effect of variation in critical raw material properties on the critical quality attributes of granules and tablets, produced by a continuous from-powder-to-tablet wet granulation line. The granulation process parameters were kept constant to examine the differences in the end product quality caused by the variability of the raw materials properties only. Theophylline-Lactose-PVP (30-67.5-2.5%) was used as model formulation. Seven different grades of theophylline were granulated. Afterward, the obtained granules were tableted. Both the characteristics of granules and tablets were determined. The results show that differences in raw material properties both affect their processability and several critical quality attributes of the resulting granules and tablets.

U2 - 10.1016/j.ejpb.2014.02.011

DO - 10.1016/j.ejpb.2014.02.011

M3 - Journal article

C2 - 24589422

VL - 87

SP - 252

EP - 263

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 2

ER -

ID: 104572739